NA
SLS icon

NewEdge Advisors’s SELLAS Life Sciences SLS Stock Holding History

NewEdge Advisors’s Portfolio SLS Stock Details SLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.38K Buy
500
+200
+67% +$1.38K ﹤0.01% 3616
2026
Q1 		$1.27K Buy
+300
New +$1.34K ﹤0.01% 3873

Other funds holding SLS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $1.68B AUM 374.17% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

NewEdge Advisors's SLS Position: Q2 2026 in Review

NewEdge Advisors increased its SELLAS Life Sciences (SLS) stake by 67% in Q2 2026, buying an estimated $1.38K and bringing the position to 500 shares worth $7.38K. The position accounts for ﹤0.01% of the portfolio, ranked #3616.

NewEdge Advisors first reported a position in SLS in Q1 2026 and has held it in 2 quarters since. 145 funds tracked by Wall St. Rank hold SLS as of Q2 2026.

  • NewEdge Advisors held 500 shares of SELLAS Life Sciences worth $7.38K as of Q2 2026.
  • NewEdge Advisors bought 200 SELLAS Life Sciences shares in Q2 2026, an estimated $1.38K.
  • SELLAS Life Sciences made up ﹤0.01% of NewEdge Advisors's portfolio in Q2 2026, its #3616 holding.
  • NewEdge Advisors first reported a position in SELLAS Life Sciences in Q1 2026 and has held it in 2 quarters since.
  • 145 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q2 2026.

Based on NewEdge Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.